- Active, not recruiting
NCT01729091: Phase 2: Umbilical Cord Blood-Derived NK Cells, Elotuzumab, Len, Melphalan f/b ASCT
Updated: Jun 15, 2022
NCT01729091: Phase 2: Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma
Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma
This phase II trial studies the side effects and best dose of umbilical cord blood-derived natural killer cells when given together with elotuzumab, lenalidomide, and high dose melphalan before autologous stem cell transplant and to see how well they work in treating patients with multiple myeloma. Before transplant, stem cells are taken from patients and stored. Immunotherapy with monoclonal antibodies, such as elotuzumab, may induce changes in the body's immune system and may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide and melphalan, may work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Giving natural killer cells from donor umbilical cord blood before transplant may also kill myeloma cells that remain in the body after the last chemotherapy treatment. After treatment, stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy.
Sponsor
M.D. Anderson Cancer Center
Collaborator
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT01729091
Official Title: Phase II Study of Umbilical Cord Blood-Derived Natural Killer Cells in Conjunction With Elotuzumab, Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant for Patients With Multiple Myeloma
First Posted: November 20, 2012
Click here to see details on ClinicalTrials.gov
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Biological: Elotuzumab
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Drug: Melphalan
Biological: Natural Killer Cell Therapy
Biological: Umbilical Cord Blood-Derived Lymphocyte Therapy
Meeting: 2022 ASCO Annual Meeting - Session Type: Clinical Science Symposium - Session Title:
Beating Bad Blood: The Power of Immunotherapy in Hematologic Malignancies - Track: Hematologic Malignancies, Hematologic Malignancies - Sub Track: Hematologic Malignancies - Clinical Trial Registration Number: NCT01729091
Abstract#: 8009 - Phase II study of umbilical cord blood–derived natural killer (CB-NK) cells with elotuzumab, lenalidomide, and high-dose melphalan followed by autologous stem cell transplantation (ASCT) for patients with high-risk multiple myeloma (HRMM)
ABSTRACTS & PRESENTATIONS
2022 ASCO ANNUAL MEETING - June 3-7, 2022 - McCormick Place, Chicago, IL - Hybrid Meeting
2022 ASCO Annual Meeting - Oral Abstract Session
Location
United States, Texas